BonesLabsBlog
Back to all posts
Uncategorized

Survodutide

Survodutide (BI 456906): A Dual GLP-1 / Glucagon Receptor Agonist

Research summary. Survodutide is a once-weekly synthetic peptide developed by Boehringer Ingelheim and Zealand Pharma as a dual agonist at the GLP-1 and glucagon receptors. Mechanistically it occupies an intermediate position between GLP-1 monoagonists (semaglutide) and the GLP-1/GIP/glucagon triple agonist retatrutide: it adds glucagon-receptor agonism to GLP-1 incretin activity but does not engage GIP. The development hypothesis is that glucagon-receptor activation drives additional energy expenditure and hepatic-fat reduction, which is of particular interest in MASH (metabolic dysfunction-associated steatohepatitis) where survodutide has shown its most distinctive Phase 2 results.

Molecular profile

  • Class: GLP-1 / glucagon dual receptor agonist (peptide)
  • Molecular formula: C₁₉₂H₂₈₉N₄₇O₆₁
  • Molecular weight: ~4290.8 g/mol
  • Synonyms: BI 456906
  • Half-life: Supports once-weekly subcutaneous administration via fatty-acid-conjugation half-life-extension chemistry

Mechanism of action

Survodutide combines two complementary mechanisms in a single peptide:

  • GLP-1 receptor agonism. Glucose-dependent insulin secretion, glucagon suppression in the postprandial state, delayed gastric emptying, and central appetite suppression — the established GLP-1 mechanism.
  • Glucagon receptor agonism. Increases hepatic energy expenditure, supports fatty-acid oxidation in the liver, and is reported to directly reduce hepatic triglyceride content. The GLP-1 component's incretin activity buffers against the glucose-elevating effect that unopposed glucagon agonism would otherwise produce.

The net pharmacological profile is intended to support weight loss and glycaemic control comparable to GLP-1 monoagonists, with additional liver-fat reductions exceeding those typical of pure GLP-1 mechanism.

Clinical research highlights

Phase 2 obesity trial. A 46-week dose-finding Phase 2 trial in adults with obesity reported placebo-subtracted weight reductions of approximately 14–19% across the higher dose ranges, supporting Phase 3 progression.

Phase 2 MASH trial (Sanyal et al., NEJM 2024). A 48-week placebo-controlled Phase 2 trial in adults with biopsy-confirmed MASH and significant fibrosis reported substantial improvements in MASH-resolution and fibrosis-reduction histological endpoints with survodutide treatment, with response rates substantially exceeding placebo. This trial is the most distinctive in the survodutide programme — the dual-glucagon-mechanism hypothesis appears most clearly supported in the MASH population.

Phase 2 type-2-diabetes trial. Survodutide has been evaluated in T2D, with reported reductions in HbA1c and body weight comparable to or greater than GLP-1 monoagonist comparators.

Phase 3 programme. A Phase 3 development programme (SYNCHRONIZE in obesity, LIVERAGE in MASH, and related T2D trials) is ongoing.

Safety profile. Adverse-effect profile in clinical trials has been broadly consistent with the incretin-agonist class, dominated by gastrointestinal effects (nausea, diarrhoea, vomiting) particularly during dose escalation.

Current research status

Survodutide is an investigational drug in late-stage clinical development. As of mid-2026 it has not been approved by the FDA. Boehringer Ingelheim and Zealand Pharma's Phase 3 programme is the registration-track effort that will support potential New Drug Applications in obesity and MASH.

Research-peptide supply of dual-agonist material is broadly available, but the regulated drug product — once approved — will be the appropriate channel for clinical use. Research-grade material is for laboratory and animal-model use only.

Key takeaways for researchers

  • Survodutide is a once-weekly dual GLP-1 / glucagon receptor agonist (BI 456906) developed by Boehringer Ingelheim and Zealand Pharma.
  • The glucagon-receptor mechanism differentiates it from GLP-1 monoagonists, targeting additional hepatic-fat reduction and energy expenditure.
  • Phase 2 results have reported substantial weight loss in obesity and substantial MASH-resolution and fibrosis-reduction endpoints in MASH; the MASH data are particularly distinctive.
  • Phase 3 programme (SYNCHRONIZE, LIVERAGE) is ongoing; survodutide is not currently FDA-approved.
  • Research-grade material is for laboratory use only.

References

  1. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311–319.
  2. Le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162–173.

This article is provided for educational and research purposes only. Survodutide is an investigational research compound. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.

Survodutide | BonesLabs